Treatment with immune checkpoint blockade (ICB) with programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1)/cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibodies has led to unprecedented durable clinical benefit for NSCLC, but response rates are low for patients with oncogenic drivers such as EGFR mutations [4,5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.